Hikma Pharmaceuticals PLC Annual report 2010 notes to tHe ComPAny FInAnCIAL stAtements Continued 54. sHAre PremIum share premium $000 Balance at 1 January 2010 980,154 Premium arising on exercise of stock options 3,183 Balance at 31 December 2010 983,337 55. net InCome For tHe yeAr As permitted by section 408 of the Companies Act 2006, the statement of comprehensive income of the Company is not presented as part of these accounts.
Included in the net income for the year is an amount of USD 12,282,000 2009: USD nil representing dividends received and USD 899,000 2009: USD 998,000 representing the current year charge of stock option and LTIPs expenses relating to the companys employees.
The remaining USD 3,574,000 2009: USD 3,618,000 of the Groups stock option and LTIPs charge is recharged to subsidiary companies.
56. reLAted PArty Transactions between the Company and its subsidiaries and associates are disclosed in Note 38.
Amounts repayable to and from subsidiaries are disclosed in Notes 45 and 48.
Other transactions with related parties include management charges for services provided to the subsidiary companies and transactions with key management personnel.
Compensation paid to key management personnel is disclosed at Note 38.
Details of Directors remuneration are disclosed in the Remuneration Committee Report on pages 66 to 68.
More details on the general information of the ultimate Parent of the Group are disclosed in Note 2.
